LACTOLOGY FOUNDATION

Cimetidine (ATC A02BA01) is generally considered compatible with breastfeeding at usual therapeutic doses, with low expected risk to the breastfed infant, but it is no longer a first‑line H2‑blocker in lactation because of relatively higher milk levels and its interaction profile.

Pharmacological class and indications

Cimetidine is a histamine H2‑receptor antagonist with antisecretory gastrointestinal action, used to reduce gastric acid secretion.
Approved indications include short‑term treatment of active duodenal and benign gastric ulcers, long‑term prophylaxis of duodenal ulcers and gastric hypersecretory states, management of gastroesophageal reflux disease, prevention of upper GI bleeding (e.g. “stress” ulcers) in critically ill patients, and treatment of heartburn (pyrosis).*
Off‑label, it has been used as part of multicomponent regimens for Helicobacter pylori eradication, as well as in certain dermatologic or immunologic conditions.

General pharmacokinetics and toxicity

After oral administration, cimetidine has an oral bioavailability of about 60–80%, with approximately 20% plasma protein binding and a volume of distribution of 1–2 l/kg.
In adults the plasma half‑life is around 2 hours, while in neonates it is reported in a similar range but with more pronounced suppression of hepatic microsomal oxidase activity.
Cimetidine is usually well tolerated; common adverse effects include diarrhea, headache, dizziness and drowsiness, while rare but clinically relevant reactions include liver enzyme elevations, confusion (especially in the elderly or renally impaired), reversible gynecomastia or impotence at high doses (>5 g/day), and hypersensitivity reactions.

In overdose, intensified CNS effects, cardiovascular instability and marked hypotension may occur, requiring supportive care and monitoring of vital functions.
Chronic high‑dose use is associated with clinically significant drug–drug interactions due to inhibition of several CYP‑isoenzymes, increasing serum levels of drugs with narrow therapeutic index (e.g. warfarin, phenytoin, theophylline, some antiarrhythmics).

Excretion into breast milk

Cimetidine is actively transported and excreted into human breast milk, achieving milk concentrations that can exceed maternal plasma levels.
The milk‑to‑plasma ratio is dose‑dependent: at a maternal daily dose of 400 mg, the plasma:milk ratio is approximately 1:1.7, whereas at 1200 mg/day it may increase to around 1:5.8.
Based on summarized data, the maximal expected cimetidine concentration in human milk has been estimated at about 37 mg/l.

Using these values, the relative infant dose (RID) is generally calculated at well under 10% of the maternal weight‑adjusted dose, with several studies and reviews citing an average infant exposure around 6–7% of the maternal dose.
This calculated exposure remains substantially below the non‑toxic therapeutic dose for neonates and infants, estimated at about 20–30 mg/kg/day, suggesting a low margin of toxicological concern under standard maternal dosing.

Clinical experience during lactation

Clinical reports and observational data have not identified adverse effects in breastfed infants whose mothers received usual therapeutic doses of cimetidine.
The LactMed database notes that cimetidine would not be expected to cause adverse effects in breastfed infants, particularly when the infant is older than 2 months.
Available pharmacokinetic studies in lactating women confirm measurable, sometimes relatively high, milk concentrations, but no clinically evident toxicity in nursing infants has been documented.

Some professional lactation resources, however, regard cimetidine as a less‑preferred H2 antagonist in breastfeeding because of its higher milk levels relative to alternatives (famotidine, ranitidine) and its extensive interaction profile, and therefore recommend other H2 blockers or proton pump inhibitors when initiating acid‑suppressive therapy in a breastfeeding mother.
There is preliminary, very limited literature suggesting that cimetidine has been explored as an adjunctive galactagogue in small series, with no major safety signals reported, but the evidence is insufficient to support routine use for this indication.

Toxicological assessment in breastfeeding

From a toxicological standpoint, cimetidine exhibits a wide therapeutic index in infants, and the maximum theoretical exposure via human milk (around 37 mg/l) remains below or close to the therapeutic range only in extreme scenarios, and still below doses associated with toxicity.
Considering the calculated RID values (<10%), the short maternal half‑life and the lack of reported serious adverse effects, the overall toxicological risk to the breastfed infant at standard maternal doses is low.

Potential theoretical risks include gastrointestinal disturbances (e.g. changes in stool pattern), transient irritability, and in very high exposures, possible interference with gastric acidity and drug metabolism in the infant, although such effects have not been convincingly demonstrated in clinical practice.
Because cimetidine can inhibit hepatic microsomal enzymes, there is a theoretical concern in preterm or medically fragile neonates receiving other hepatically cleared drugs, warranting increased vigilance if maternal cimetidine therapy is considered essential.

Use during pregnancy and peripartum

Data from animal studies and human clinical exposure have not demonstrated teratogenicity, and regulatory documents generally classify cimetidine in pregnancy category B, acknowledging that it crosses the placenta.
According to several product characteristics, use during pregnancy and lactation is recommended only when clearly essential, reflecting a precautionary approach rather than specific evidence of harm.

In the peripartum period, the same pharmacokinetic properties apply; initiation or continuation of cimetidine in the immediate postpartum phase should balance maternal benefit against the availability of safer alternative acid‑suppressive agents for breastfeeding women.

Practical lactation recommendations

For otherwise healthy term infants, maternal cimetidine therapy at standard oral doses is generally considered compatible with breastfeeding without the need for routine interruption of nursing.
When initiating acid‑suppressive therapy de novo in a lactating woman, alternative H2 antagonists with lower milk penetration (e.g. famotidine) or suitable proton pump inhibitors are usually preferred, reserving cimetidine for situations where there is specific clinical justification.

If cimetidine is used, it is reasonable, though not strictly necessary, to administer the maternal dose immediately after breastfeeding or before the infant’s longest sleep interval to further minimize peak infant exposure.
Infant monitoring can focus on general wellbeing, feeding pattern, weight gain and stool characteristics; no specific laboratory monitoring is routinely required in healthy term infants but may be considered in preterm or medically complex babies.